iifl-logo

Neuland Laboratories Ltd Annually Results

12,069
(-1.70%)
Apr 30, 2025|02:34:55 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,558.58

1,191.2

951.08

936.91

762.71

Excise Duty

0

0

0

0

0

Net Sales

1,558.58

1,191.2

951.08

936.91

762.71

Other Operating Income

0

0

0

0

0

Other Income

12.54

9.75

2.08

16.1

3.89

Total Income

1,571.12

1,200.95

953.15

953.01

766.6

Total Expenditure

1,095.99

919.36

808.46

790.09

660.82

PBIDT

475.13

281.59

144.7

162.91

105.78

Interest

14

13.07

13.5

17.9

21.57

PBDT

461.14

268.52

131.2

145.02

84.2

Depreciation

59.7

52.78

49.04

39.68

31.28

Minority Interest Before NP

0

0

0

0

0

Tax

99.67

50.44

20.43

12.56

0.1

Deferred Tax

1.69

1.79

-2.09

12.15

36.62

Reported Profit After Tax

300.08

163.52

63.82

80.63

16.21

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

300.08

163.52

63.82

80.63

16.21

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

300.08

163.52

63.82

80.63

16.21

EPS (Unit Curr.)

233.89

127.45

49.74

62.85

12.63

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

140

100

50

50

20

Equity

12.9

12.9

12.9

12.9

12.9

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

30.48

23.63

15.21

17.38

13.86

PBDTM(%)

29.58

22.54

13.79

15.47

11.03

PATM(%)

19.25

13.72

6.71

8.6

2.12

Neuland Labs.: Related NEWS

Neuland Laboratories tumbles ~7% as 3.8% shares change hands
12 Dec 2024|02:19 PM

The transaction takes place against the backdrop of a more than 9% reduction in the stock's value during the previous week.

Read More
Neuland Laboratories gets USFDA approval for Schizophrenia Drug
27 Sep 2024|03:17 PM

However, it is unclear whether the Hyderabad-based company will be Cobenfy's exclusive supplier.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.